Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...

Barclays analyst Emily Field maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The company’s shares closed yesterday at p9,999.00. According to ...

AstraZeneca AZN0.05%increase; green up pointing triangle said it plans to pump $2 billion in new investment into the U.S., ...

After hitting record highs following Trump’s victory, the Dow and S&P 500 hit the brakes on Tuesday, a day before the release ...

Shares of AstraZeneca PLC AZN inched up 0.05% to £99.90 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index UKX falling 1.22% to 8,025.77.

AstraZeneca (AZN) said it plans to spend $3.5B to expanding its research and manufacturing capabilities in the United States ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

U.S. investment of $3.5 billion announced to bolster research and manufacturing. AstraZeneca Plc AZN reported third-quarter ...

KEY TAKEAWAYS British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

CAMBRIDGE, Britain — CAMBRIDGE, Britain — Astrazeneca PLC (AZN) on Tuesday reported third-quarter earnings of $1.43 billion. On a per-share basis, the Cambridge, Britain-based company said it had ...